How Herpes Simplex Hides: Latency, Immunity, and Where Treatment Research Stands

Most people who carry herpes simplex virus don’t know it. The virus is one of the most widespread infections in humans, and for most carriers it causes mild symptoms or none. It also has a trick few other viruses can match. After the first infection, it retreats into nerve cells and stays there for life, mostly silent, sometimes waking up. This article covers how that hiding works, how the immune system pushes back, what today’s treatments can and cannot do, and where research honestly stands as of November 2026.

How common is HSV?

The World Health Organization’s latest figures are based on modelling estimates for 2020. They put the number of people under 50 living with HSV-1, the virus behind most oral herpes (cold sores), at about 3.8 billion, or 64% of that age group. About 520 million people aged 15–49, roughly 13%, have HSV-2, the main cause of genital herpes [1]. The underlying modelling study also estimated that about 205 million people aged 15–49 had at least one symptomatic genital herpes episode in 2020 [2]. HSV-1 now causes a substantial share of genital infections as well, mostly through oral–genital contact [1, 2].

These numbers matter for more than statistics. Herpes is common, usually mild, and often unrecognized. Infection says nothing about a person’s character or hygiene. WHO notes that most infections are asymptomatic or go unrecognized, and that HSV-2 infection roughly triples the risk of acquiring HIV [1]. That is one reason public-health researchers treat herpes as a serious target and not just a nuisance.

The life cycle: infection, latency, reactivation

First infection

HSV enters through mucous membranes or small breaks in the skin of the mouth, genitals, or elsewhere. It replicates in the skin’s outer cells (keratinocytes) and can produce the familiar blisters and ulcers, although many first infections cause few or no symptoms. During this phase the virus also enters the endings of sensory nerves that supply the area.

Latency: hiding in sensory neurons

Inside the nerve fiber, the virus travels back to the nerve cell body in a sensory ganglion. For oral infection this is usually the trigeminal ganglion near the base of the skull. For genital infection it is the sacral ganglia near the lower spine. There the viral DNA sits in the nucleus as a separate circle and does not insert into the cell’s own chromosomes. The cell packages it in chromatin, the same protein scaffolding that regulates human genes, and most viral genes are switched off [3]. One region of the viral genome stays active and produces the latency-associated transcript (LAT) and related small RNAs, which help keep the virus in its quiet state [3].

This quiet state, called latency, is the central reason HSV cannot currently be cured. Latent virus makes almost no viral proteins. The immune system therefore has little to detect, and antiviral drugs, which act on actively copying virus, have nothing to hit.

Reactivation: waking up

From time to time, latent virus in some neurons switches its genes back on, makes new virus particles, and sends them back down the nerve fiber to the skin or mucosa near the original site of infection. Laboratory research shows that reactivation is not a single on/off switch. Several different stress signals inside the neuron can start it, including signalling pathways triggered by nerve stress, loss of growth-factor support, and stress hormones [4]. This matches what people with recurrent herpes often report: outbreaks after illness or fever, intense sunlight on the lips, physical or emotional stress, local trauma, or hormonal changes. Weakened immunity, for example from some medicines or advanced HIV, can make reactivations more frequent and more severe.

Not every reactivation produces a sore. As the next sections explain, many episodes are shut down in the skin before anyone notices them.

How the immune system keeps HSV in check

The immune system can’t currently clear latent virus from neurons, but it is very good at containing what comes out of them. Research led largely by groups at the University of Washington and Fred Hutchinson Cancer Center has changed how scientists picture this contest.

A fast, local response

Studies that combined frequent genital swabbing with mathematical modelling show that HSV-2 reactivates far more often than outbreaks suggest. Most of these episodes are contained within hours to a few days [5]. Containment depends on how quickly the local immune response kicks in. Innate defenses, such as interferons and resident immune cells that sense infected cells, act within hours. Memory T cells already parked at the site do the rest [5].

Tissue-resident memory T cells: guards at the nerve endings

A key finding is that HSV-specific CD8+ T cells don’t simply circulate in the blood waiting to be recruited. In serial biopsies of human genital skin, a population of CD8+ T cells (a subset expressing CD8αα) lives permanently at the dermal–epidermal junction, the boundary between the outer and deeper layers of the skin. That is exactly where nerve endings release reactivating virus [6]. These tissue-resident memory cells persisted at the same sites across recurrences for years, and episodes that were contained rapidly without symptoms were associated with a high local density of these cells [6].

In practical terms, every place that has had a herpes lesion becomes a guarded checkpoint. The balance between how much virus arrives and how many immune “guards” are waiting may help explain why outbreaks vary so much between people and over time.

Asymptomatic shedding and transmission

Because many reactivations never produce a visible sore, people can shed infectious virus from the skin or mucosa without symptoms. In a large study of people with HSV-2 who collected daily genital swabs, virus was detected on about 20% of days in people with a history of symptomatic genital herpes. In people who had never had recognized symptoms (diagnosed only by blood test), it was detected on about 10% of days. Most shedding in the asymptomatic group happened without lesions, and the amount of virus during subclinical shedding was similar between groups [7].

This is a main reason HSV spreads so efficiently: the virus can pass on when there are no sores, often from people who don’t know they are infected [1, 7]. That is a biological feature of the virus, not a reason for blame, and it is why approaches that reduce shedding, not just outbreaks, matter.

What treatment can do today

Approved antivirals

The standard drugs are acyclovir, valacyclovir (a better-absorbed form of acyclovir), and famciclovir. All three are nucleoside analogues that block the viral DNA polymerase once the virus is actively replicating. U.S. CDC guidelines describe two main ways of using them [8]:

• Episodic therapy, started at the first sign of an outbreak (ideally during the tingling “prodrome” or within about a day of lesions appearing), which shortens and softens episodes. The three drugs appear similarly effective for this purpose [8].
• Daily suppressive therapy, which reduces recurrences by roughly 70–80% in people with frequent outbreaks and is safe for long-term use, with resistance uncommon in people with healthy immune systems [8].

CDC also states plainly that these drugs do not eradicate latent virus. Once treatment stops, they do not change how often or how severely the infection recurs [8].

Reducing transmission

The landmark study here is a 2004 New England Journal of Medicine trial led by Lawrence Corey. It enrolled 1,484 heterosexual couples in which one partner had symptomatic genital HSV-2 and the other did not. Once-daily valacyclovir in the infected partner reduced symptomatic HSV-2 infection in the uninfected partner from 16 cases to 4 (a 75% relative reduction). Overall HSV-2 acquisition fell from 3.6% to 1.9% over eight months. Genital shedding dropped from 10.8% to 2.9% of days [9]. The benefit was real but incomplete. CDC recommends combining suppressive therapy with consistent condom use and avoiding sex during symptoms or prodrome, and notes that condoms reduce but don’t eliminate risk [8].

For cold sores

For oral herpes (herpes labialis), a Cochrane systematic review found that long-term oral antiviral prophylaxis reduces recurrences, though the clinical benefit was small, with moderate-quality evidence [10].

What about lysine and other supplements?

L-lysine is widely promoted for cold sores. The same Cochrane review of preventive interventions found no evidence that lysine prevents herpes labialis recurrences [10]. That doesn’t prove it can never help anyone, but the controlled evidence doesn’t support relying on it. No supplement, diet, or “natural protocol” has been shown in controlled trials to eliminate latent HSV. Claims that something “cures herpes” should be treated with strong skepticism.

Research pipeline

Helicase-primase inhibitors: a new drug class reaches the clinic

Helicase-primase inhibitors block a different viral enzyme complex from the one targeted by acyclovir-type drugs. They don’t need activation by a viral enzyme, which means they may work against strains resistant to standard drugs.

• Pritelivir. In a randomized trial in people with frequently recurring genital herpes, pritelivir reduced genital HSV-2 shedding (2.4% vs 5.3% of swabs) and days with lesions compared with valacyclovir. The trial was stopped early after an FDA clinical hold [11]. Development continued, and on the basis of the phase 3 PRIOH-1 trial in immunocompromised adults, the FDA approved pritelivir (brand name Hovilpri) in October 2026. The approved use is for mucocutaneous HSV lesions that are refractory to acyclovir, valacyclovir, or famciclovir (with or without documented resistance) in immunocompromised adults [12]. In that trial, 63% of pritelivir-treated participants had complete lesion healing by day 28, compared with 34% on investigator’s-choice therapy [12]. This is a meaningful advance for a small, hard-to-treat group. It is not an approval for routine genital or oral herpes in otherwise healthy people, and it does not clear latent virus.
• Amenamevir. Amenamevir has been approved in Japan since 2017 for shingles (herpes zoster). A published study report states it was approved there in February 2023 for recurrent herpes simplex, including patient-initiated single-dose treatment [13]. In a phase 3 placebo-controlled trial in recurrent genital herpes, a single patient-initiated dose shortened median time to healing from 5.1 to 4.0 days [14]. It isn’t approved in the United States or Europe.

Vaccines: a long, humbling road

No herpes vaccine is approved anywhere [1]. The best-known failure is the Herpevac Trial for Women, which tested a glycoprotein D subunit vaccine in more than 8,300 HSV-seronegative women. It showed no significant protection against genital herpes disease overall and no efficacy against HSV-2 infection. Unexpectedly, it showed partial protection against genital HSV-1 disease [15]. That result pushed the field toward different antigens, adjuvants, and platforms.

Current efforts include both prophylactic vaccines (to prevent infection) and therapeutic vaccines (to reduce outbreaks and shedding in people already infected):

• Moderna’s mRNA-1608 (therapeutic, HSV-2). A phase 1/2 trial in about 300 adults with recurrent genital herpes reported, in an interim conference abstract, increased antibody and mainly CD4+ T-cell responses. It found only a trend toward longer time to first recurrence and lower recurrence rates, with no safety concerns identified [16]. In November 2025 Moderna said it would halt work on the candidate and that it would not advance to late-stage development [17].
• BioNTech’s BNT163 (prophylactic, HSV-2 and potentially HSV-1). A phase 1 dose-escalation and safety trial with 318 participants is listed on ClinicalTrials.gov as active, not recruiting, with no results posted as of its October 2026 update [18].

Early immune responses are encouraging scientifically. But no candidate has yet shown in a large trial that it prevents infection or meaningfully reduces disease.

Gene editing: aiming at the latent reservoir

Because latency is what makes HSV incurable, some researchers are trying to damage the hidden viral DNA directly. A Fred Hutchinson team led by Martine Aubert and Keith Jerome used adeno-associated virus (AAV) vectors to deliver meganucleases, enzymes that cut specific DNA sequences, into the ganglia of infected mice. In a 2020 study, this removed more than 90% of latent HSV-1 DNA from a ganglion in a mouse model [19]. A 2024 follow-up reported elimination of at least 90% of latent virus in orofacial models and up to 97% in genital models. Lower ganglionic viral load was linked to reduced viral shedding after induced reactivation. The work also found liver toxicity at high doses, which a simplified single-vector approach improved [20].

These results are a genuine scientific milestone. They are animal data, not a human cure. Questions about safety, delivery to every relevant ganglion in humans, durability, and off-target effects remain to be answered in clinical trials.

At a glance

Approach	Stage (as of Nov 2026)	Key caveat
Acyclovir, valacyclovir, famciclovir	Approved; standard of care	Reduce outbreaks and transmission; don’t remove latent virus
Pritelivir (helicase-primase inhibitor)	FDA-approved Oct 2026 for refractory HSV in immunocompromised adults	Narrow indication; not approved for routine herpes
Amenamevir (helicase-primase inhibitor)	Approved in Japan (zoster 2017; recurrent HSV reported 2023)	Not approved in US/EU
gD subunit vaccine (Herpevac)	Failed phase 3 (2012)	No protection against HSV-2
mRNA-1608 (therapeutic vaccine)	Phase 1/2 completed; development halted	Only exploratory trends in recurrence
BNT163 (preventive mRNA vaccine)	Phase 1	Safety/immune data only; no efficacy results
Meganuclease gene editing	Preclinical (mice)	Animal data; no human trials reported in cited work

What the evidence does and doesn’t support

Well supported:

• HSV establishes lifelong latency in sensory neurons and reactivates intermittently [3, 4].
• Local immune responses, including tissue-resident CD8+ T cells, contain most reactivations quickly, often without symptoms [5, 6].
• Asymptomatic shedding is common and accounts for much transmission [7].
• Standard antivirals shorten outbreaks, reduce recurrences, and lower (but don’t eliminate) the risk of transmitting genital HSV-2 to a partner [8, 9].

Emerging or limited:

• Helicase-primase inhibitors are now a real clinical option for specific situations [12, 14], but their role in routine care is still undefined outside Japan.
• Vaccine candidates have produced immune responses, but none has proven protection [15, 16, 18].
• Gene editing has reduced latent virus in mice [19, 20], which is far from a demonstrated cure in people.

Not supported:

• Claims that any supplement, diet, or alternative product cures herpes or removes latent virus.
• Lysine for preventing cold sores, based on the available controlled trials [10].

Questions to ask your clinician

• Which type of HSV do I have, and how was that determined? Would type-specific testing change anything for me?
• Given how often I have outbreaks, would episodic or suppressive therapy make more sense?
• How much would suppressive therapy reduce the risk of passing HSV to my partner, and what else can we do together to lower that risk?
• Are there situations (pregnancy, a weakened immune system, eye symptoms) where I should seek care right away?
• If my outbreaks don’t respond to standard treatment, could resistance be a factor, and what are the options?
• Are there clinical trials I might be eligible for?

Bottom line

Herpes simplex is extremely common, usually mild, and not a reflection of anyone’s worth. The virus persists because it hides in nerve cells, where today’s drugs and the immune system can’t reach it, though the body mounts a fast, well-organized defense in the skin. Standard antivirals are safe, effective tools for reducing outbreaks and transmission. In 2026 a new drug class reached U.S. patients with hard-to-treat infections. Vaccines and gene editing are active, serious research areas, but neither has yet shown it can prevent or cure HSV in people. Be cautious of anyone selling a cure, and stay hopeful about the science.

References

1. World Health Organization. Herpes simplex virus [fact sheet]. 30 May 2025. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
2. Harfouche M, AlMukdad S, Alareeki A, et al. Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses. Sex Transm Infect. 2025;101(4):214-223. https://pubmed.ncbi.nlm.nih.gov/39658199/
3. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol. 2008;6(3):211-221. https://pubmed.ncbi.nlm.nih.gov/18264117/
4. Suzich JB, Cliffe AR. Strength in diversity: understanding the pathways to herpes simplex virus reactivation. Virology. 2018;522:81-91. https://pubmed.ncbi.nlm.nih.gov/30014861/
5. Schiffer JT, Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med. 2013;19(3):280-290. https://pubmed.ncbi.nlm.nih.gov/23467247/
6. Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature. 2013;497(7450):494-497. https://pubmed.ncbi.nlm.nih.gov/23657257/
7. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441-1449. https://pubmed.ncbi.nlm.nih.gov/21486977/
8. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. https://pubmed.ncbi.nlm.nih.gov/34292926/ (Genital herpes section: https://www.cdc.gov/std/treatment-guidelines/herpes.htm)
9. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11-20. https://pubmed.ncbi.nlm.nih.gov/14702423/
10. Chi CC, Wang SH, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015;(8):CD010095. https://pubmed.ncbi.nlm.nih.gov/26252373/
11. Wald A, Timmler B, Magaret A, et al. Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial. JAMA. 2016;316(23):2495-2503. https://pubmed.ncbi.nlm.nih.gov/27997653/
12. Asahi Kasei Therapeutics. Asahi Kasei Therapeutics announces FDA approval of HOVILPRI (pritelivir) tablets for mucocutaneous HSV lesions refractory (with or without resistance) to standard antiviral treatment in immunocompromised adults [press release]. 13 October 2026. https://www.asahi-kasei.com/news/2026/e261013
13. Koinuma S, Goto M, Saito J, et al. Transfer of amenamevir into breast milk in breastfeeding patients with recurrent herpes simplex: study protocol for a single-arm, open-label study. Front Pediatr. 2025;13:1551335. https://pubmed.ncbi.nlm.nih.gov/40276108/
14. Kawashima M, Imafuku S, Fujio K, et al. Single-dose, patient-initiated amenamevir therapy for recurrent genital herpes: a phase 3, randomized, double-blind, placebo-controlled study. Open Forum Infect Dis. 2022;9(10):ofac494. https://pubmed.ncbi.nlm.nih.gov/36267254/
15. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366(1):34-43. https://pubmed.ncbi.nlm.nih.gov/22216840/
16. Wald A, Comeaux CA, Embry A, et al. mRNA-1608, an mRNA-based therapeutic genital herpes vaccine candidate: interim safety, immunogenicity and clinical endpoint results from a phase 1/2, randomized, observer-blind, controlled, dose-ranging trial [abstract 642]. Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.206. https://pmc.ncbi.nlm.nih.gov/articles/PMC12792503/ (Trial record: https://clinicaltrials.gov/study/NCT06033261)
17. Manalac T. Moderna cans 3 mRNA vaccines, secures $1.5B loan in quest for 10% growth. BioSpace. 21 November 2025. https://www.biospace.com/business/moderna-cans-3-mrna-vaccines-secures-1-5b-loan-in-quest-for-10-growth
18. BioNTech SE. Safety, tolerability, and immunogenicity of an investigational prophylactic vaccine (BNT163) for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. ClinicalTrials.gov identifier NCT05432583. Updated 22 October 2026. https://clinicaltrials.gov/study/NCT05432583
19. Aubert M, Strongin DE, Roychoudhury P, et al. Gene editing and elimination of latent herpes simplex virus in vivo. Nat Commun. 2020;11(1):4148. https://pubmed.ncbi.nlm.nih.gov/32811834/
20. Aubert M, Haick AK, Strongin DE, et al. Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo. Nat Commun. 2024;15(1):4018. https://pubmed.ncbi.nlm.nih.gov/38740820/

This article is for educational purposes only and is not medical advice. Talk with a qualified healthcare professional about diagnosis, testing, and treatment.